Bristol Myers Squibb (CELG-RI) Dividends payables (2009 - 2015)
Bristol Myers Squibb (CELG-RI) posted quarterly Dividends payables of $655.0 million for Q4 2015, up 1.55% year-over-year from $645.0 million in Q4 2014, and up 2.99% quarter-over-quarter from $636.0 million in Q3 2015.
Bristol Myers Squibb (CELG-RI) Dividends payables (2009 - 2015) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Dividends payables for 7 consecutive years, with $655.0 million the latest figure, recorded in Q4 2015.
- In Q4 2015, Dividends payables rose 1.55% year-over-year to $655.0 million; the TTM figure through Dec 2015 stood at $655.0 million (up 1.55% YoY), while the FY2015 annual figure was $655.0 million, up 1.55% from the prior year.
- Dividends payables improved to $655.0 million in Q4 2015 per CELG-RI's latest filing, from $636.0 million in the prior quarter.
- Across five years, Dividends payables topped out at $655.0 million in Q4 2015 and bottomed at $578.0 million in Q1 2011.
- Historically, Dividends payables has averaged $612.2 million across 5 years, with a median of $608.5 million in 2012.
- On a YoY basis, Dividends payables climbed as much as 4.62% in 2013 and fell as far as 1.34% in 2013.
- Bristol Myers Squibb's Dividends payables stood at $597.0 million in 2011, then advanced by 1.51% to $606.0 million in 2012, then rose by 4.62% to $634.0 million in 2013, then grew by 1.74% to $645.0 million in 2014, then rose by 1.55% to $655.0 million in 2015.
- Business Quant data shows CELG-RI's Dividends payables at $655.0 million in Q4 2015, $636.0 million in Q3 2015, and $634.0 million in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn | - |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn | 2.13 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 2.45 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 655.00 Mn |
| Sep 30, 2015 | 636.00 Mn |
| Jun 30, 2015 | 634.00 Mn |
| Mar 31, 2015 | 633.00 Mn |
| Dec 31, 2014 | 645.00 Mn |
| Sep 30, 2014 | 623.00 Mn |
| Jun 30, 2014 | 621.00 Mn |
| Mar 31, 2014 | 619.00 Mn |
| Dec 31, 2013 | 634.00 Mn |
| Sep 30, 2013 | 611.00 Mn |
| Jun 30, 2013 | 606.00 Mn |
| Mar 31, 2013 | 601.00 Mn |
| Dec 31, 2012 | 606.00 Mn |
| Sep 30, 2012 | 596.00 Mn |
| Jun 30, 2012 | 598.00 Mn |
| Mar 31, 2012 | 593.00 Mn |
| Dec 31, 2011 | 597.00 Mn |
| Sep 30, 2011 | 578.00 Mn |
| Jun 30, 2011 | 579.00 Mn |
| Mar 31, 2011 | 578.00 Mn |